Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Respir Cell Mol Biol ; 52(6): 762-71, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25353067

RESUMEN

Inspiratory resistive breathing (RB), encountered in obstructive lung diseases, induces lung injury. The soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway is down-regulated in chronic and acute animal models of RB, such as asthma, chronic obstructive pulmonary disease, and in endotoxin-induced acute lung injury. Our objectives were to: (1) characterize the effects of increased concurrent inspiratory and expiratory resistance in mice via tracheal banding; and (2) investigate the contribution of the sGC/cGMP pathway in RB-induced lung injury. Anesthetized C57BL/6 mice underwent RB achieved by restricting tracheal surface area to 50% (tracheal banding). RB for 24 hours resulted in increased bronchoalveolar lavage fluid cellularity and protein content, marked leukocyte infiltration in the lungs, and perturbed respiratory mechanics (increased tissue resistance and elasticity, shifted static pressure-volume curve right and downwards, decreased static compliance), consistent with the presence of acute lung injury. RB down-regulated sGC expression in the lung. All manifestations of lung injury caused by RB were exacerbated by the administration of the sGC inhibitor, 1H-[1,2,4]oxodiazolo[4,3-]quinoxalin-l-one, or when RB was performed using sGCα1 knockout mice. Conversely, restoration of sGC signaling by prior administration of the sGC activator BAY 58-2667 (Bayer, Leverkusen, Germany) prevented RB-induced lung injury. Strikingly, direct pharmacological activation of sGC with BAY 58-2667 24 hours after RB reversed, within 6 hours, the established lung injury. These findings raise the possibility that pharmacological targeting of the sGC-cGMP axis could be used to ameliorate lung dysfunction in obstructive lung diseases.


Asunto(s)
Guanilato Ciclasa/metabolismo , Enfermedades Pulmonares Obstructivas/enzimología , Lesión Pulmonar/enzimología , Resistencia de las Vías Respiratorias , Animales , Benzoatos/farmacología , Benzoatos/uso terapéutico , GMP Cíclico/metabolismo , Evaluación Preclínica de Medicamentos , Activación Enzimática , Guanilato Ciclasa/antagonistas & inhibidores , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Lesión Pulmonar/tratamiento farmacológico , Masculino , Ratones Endogámicos C57BL
2.
Am J Chin Med ; 39(6): 1193-206, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22083990

RESUMEN

The aim of this study was to investigate the influence of scutellarin on mucus production induced by human neutrophil elastase (HNE) and the possible in vitro and in vivo mechanisms. To this purpose, cells were incubated with saline, scutellarin or gefitinib for 60 min and exposed to 0.1 µM HNE for 24 h. After being pretreated respectively with saline, scutellarin or gefitinib, rats were challenged intratracheally with HNE by means of nebulization for 30 days. The expression of mucin (MUC) 5AC, protein kinase C (PKC), and extracellular signal-regulated kinase 1/2 (ERK1/2) was assessed by ELISA, RT-PCR or Western blotting. The results showed that scutellarin inhibited MUC5AC mRNA and protein expressions induced by HNE in a concentration-dependent manner in vitro. In the in vivo model, scutellarin significantly attenuated MUC5AC mRNA expression and goblet cell hyperplasia in rats treated with HNE for 30 days, as well as decreased the phosporylation of PKC and ERK1/2 compared to the HNE control group. Therefore, our study showed that scutellarin could prevent mucus hypersecretion by inhibiting the PKC-ERK signaling pathway. Inhalation scutellarin may be valuable in the treatment of chronic inflammatory lung disease.


Asunto(s)
Apigenina/farmacología , Medicamentos Herbarios Chinos/administración & dosificación , Glucuronatos/farmacología , Elastasa de Leucocito/metabolismo , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Enfermedades Pulmonares Obstructivas/metabolismo , Mucina 5AC/genética , Transducción de Señal/efectos de los fármacos , Animales , Línea Celular , Erigeron , Humanos , Elastasa de Leucocito/genética , Enfermedades Pulmonares Obstructivas/enzimología , Enfermedades Pulmonares Obstructivas/genética , Masculino , Proteína Quinasa 1 Activada por Mitógenos/genética , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/genética , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Mucina 5AC/metabolismo , Proteína Quinasa C/genética , Proteína Quinasa C/metabolismo , Ratas , Ratas Sprague-Dawley
3.
Ugeskr Laeger ; 160(25): 3736-9, 1998 Jun 15.
Artículo en Danés | MEDLINE | ID: mdl-9641061

RESUMEN

Patients with COLD may develop Mg depletion due to inadequate nutrition or treatment with diuretics and beta 2-agonists. In 36 consecutive COLD patients skeletal muscle concentrations of Mg and K were reduced by 22% and 14%, respectively, compared to 23 age- and sex-matched controls (p < 0.001). Patients receiving diuretics showed a further reduction of muscle Mg (-31%) and K (-27%) compared to controls. The mean concentration of Na,K pumps was increased by 31% (p < 0.001), while a more pronounced increase (+61%) was seen in 12 intensive care patients receiving high dosages of glucocorticoids. Thus muscle concentrations of Mg and K are reduced in COLD patients and are associated with an upregulation of the Na,K-pump concentration. It is plausible that this upregulation may be caused by glucocorticoid treatment. The clinical benefits of glucocorticoids may therefore in part be due to an increased activity and capacity of the Na,K-pump and thereby in a possible enhancement of muscle force.


Asunto(s)
Diuréticos/efectos adversos , Enfermedades Pulmonares Obstructivas/metabolismo , Deficiencia de Magnesio/etiología , Magnesio/análisis , Músculo Esquelético/metabolismo , ATPasa Intercambiadora de Sodio-Potasio/análisis , Adulto , Anciano , Antiinflamatorios/administración & dosificación , Diuréticos/uso terapéutico , Femenino , Glucocorticoides/administración & dosificación , Humanos , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Enfermedades Pulmonares Obstructivas/enzimología , Masculino , Persona de Mediana Edad , Músculo Esquelético/enzimología , Ouabaína/análisis , Prednisolona/administración & dosificación
4.
Zhonghua Jie He He Hu Xi Za Zhi ; 13(2): 99-101, 127-8, 1990 Apr.
Artículo en Chino | MEDLINE | ID: mdl-2397539

RESUMEN

We have observed the influence of Radix Salviae Miltiorrhizae and Ligustrazini Hydrochloridum on the elastase activity and the protective effects of the two medicines on the elastic fibers. The results showed that Radix Salviae Miltiorrhizae and Ligustrazini Hydrochloridum can inhibit the activity of porcine pancreatic elastase and human sputum elastase. These two drugs can protect arterial and pulmonary elastic fibers from the destruction of elastase. Since these traditional Chinese herbs have little toxic effect and no antigenic character, they can be used in the preventing emphysema. The study suggest that it is useful Radix Salviae Miltiorrhizae and Ligustrazini Hydrochloridum are as favourable elastase inhibiting agents, which may be used in the prevention of emphysema extensively.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Enfisema/prevención & control , Elastasa Pancreática/antagonistas & inhibidores , Fenantrolinas/farmacología , Extractos Vegetales , Pirazinas/farmacología , Animales , Aorta/efectos de los fármacos , Combinación de Medicamentos/farmacología , Tejido Elástico/efectos de los fármacos , Humanos , Pulmón/efectos de los fármacos , Enfermedades Pulmonares Obstructivas/enzimología , Conejos , Salvia miltiorrhiza
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA